US00287Y1091 - Common Stock - Premarket: 146 -0.28 (-0.19%)
NYSE:ABBV (1/27/2023, 7:04:00 PM)-1.12 (-0.76%)
|GICS Sector||Health Care|
|Earnings (Last)||10-28 2022-10-28/bmo||Earnings (Next)||01-31 2023-01-31|
|Ins Owners||0.1%||Inst Owners||69.2%|
Find more stocks on New York Stock Exchange, Inc.
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The company offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta; aesthetics products that include Botox Cosmetic, Juvederm Collection and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products consists of Lumigan, Alphagan and Restasis; women's health products include Lo Loestrin, Orilissa and others; and other products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. Its products are sold to wholesalers, government agencies, health care facilities and independent retailers. The company also discovers and develop antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).
1 N Waukegan Rd
North Chicago ILLINOIS 60064
CEO: Richard A. Gonzalez
After adding $208B in sales over two decades, AbbVie's (ABBV) monopoly over world's best selling drug Humira (adalimumab) is about to end as copycats enter. Read the full story here.
Dividend stocks are a hedge against volatile markets. Here are seven dividend stocks that you should buy now before you regret missing out.
You can count on them for passive income and growth over time.
A committee of the European Medicines Agency ((EMA)) said that Johnson & Johnson (JNJ) withdrew its application seeking expanded approval of blood cancer drug Imbruvica on Dec
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.
Here you can normally see the latest stock twits on ABBV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.